Overview
Our lab studies fibrosis, specifically the interactions between mast cells and fibroblasts; mast cells reside in close proximity to fibroblasts. Our goals are identifying new anti-fibrotic targets and designing novel therapeutic compounds to prevent fibrosis.
The goal of the Silver Laboratory is to define the mechanisms by which fibrosis occurs. Fibrosis impacts a significant portion of the global population and is a growing public health concern. A hallmark of fibrosis is the increased expression of fibroblast transforming growth factor-β (TGF-β) and the subsequent activation of collagen genes. Large-scale clinical studies of pharmacologic therapy for inhibiting organ fibrosis have predominantly focused on TGF-β and associated signaling pathways involved in the translation of collagenous peptides. However, due to its multi-functionality, targeting TGF- β signaling has a higher likelihood of adverse effects. Plus, TGF- β is not the only pathway contributing to fibrosis. Not surprisingly then, the preponderance of clinical trial evidence suggests that TGF- β-targeted therapies are only partially beneficial, often with poor tolerability. There is a great need for a deeper understanding of the cellular and molecular mechanisms underlying pathological fibrosis and new therapeutic approaches.
The lab’s research focuses on the interactions between mast cells and fibroblasts, the cells responsible for fibrosis. (Figure 1. see electron micrograph showing spatial relationship between mast cell and fibroblasts). The association between mast cells and fibroblasts has long been appreciated but the cross-talk and mechanistic interactions between. n them are not well defined. We use parallel in vivo and in vitro functional, biochemical, and cell biological approaches to analyze how mast cells and fibroblasts interact to promote fibrosis. The Silver lab has identified numerous pro-fibrotic chemicals and vesicles (exosomes) that are released from mast cells that stimulate fibroblasts and fibrosis. Silver’s studies have identified new therapeutic targets for abating fibrosis. Building on our findings we are utilizing in silico drug design to inform novel anti-fibrotic therapeutics.
Highlights
- 1Frontiers in medicine · 2023
Publications
Funding
Active
1 grant- Sub-PIR42HL176297-02Fast Track Phase II - Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4HNational Heart, Lung, and Blood Institute · 2024–2027 · via Adiutrix Therapeutics, LLC· 2 renewals
Completed grants (4)
- Sub-PICUI 235199-01Development of Small Molecule Inhibitors of Collagen Prolyl-4 Hydroxylase (CP4H) to Treat FibrosisNYSTAR · 2024–2025 · via Cornell University - Ithaca
- PIDFI 202950-02Development of Novel Drugs to Treat Fibrosis Through Modulation of Collagen Prolyl-4-HydroxylaseDaedalus Fund for Innovation (Weill Cornell) · 2020–2023BioPharma Alliance
- KPR01HL034215-37EWOHistamine Receptor/Norepinephrine in Cardiac DysfunctionNational Heart, Lung, and Blood Institute · 2010–2015
- PIR01DK060726-08 EWMast-Cell Renin and Local ANG II FormationNational Institute of Diabetes and Digestive and Kidney Diseases · 2007–2011
News mentions
- Science and Community Shine at 44th Vincent du Vigneaud SymposiumMay 1, 2025
The Griffis Faculty Club buzzed with excitement as doctoral students from the Weill Cornell Graduate School of Medical Sciences presented their research, drawing peers, faculty and alumni to the 44th annual Vincent du Vigneaud Symposium on April 24.
- Conference Showcases Biomedical Innovation at the Intersection of Business and ScienceMarch 7, 2024
The 2024 Startup Symposium & InvestConnect Conference celebrated scientific inquiry and the entrepreneurial spirit.
- New Class of Physician Assistant Students Receive Their White CoatsMay 11, 2023
On May 5, Rubin was one of the 47 students in the Class of 2025 to receive their short white coats, gathered before an audience of faculty, family and friends at Griffis Faculty Club as part of the annual white coat ceremony.
Mentoring
- ASAlexandria SavagePhysiology, Biophysics & Systems Biology (PhD) · Class of 2019